[go: up one dir, main page]

MX9700374A - Formulaciones acuosas de risperidona. - Google Patents

Formulaciones acuosas de risperidona.

Info

Publication number
MX9700374A
MX9700374A MX9700374A MX9700374A MX9700374A MX 9700374 A MX9700374 A MX 9700374A MX 9700374 A MX9700374 A MX 9700374A MX 9700374 A MX9700374 A MX 9700374A MX 9700374 A MX9700374 A MX 9700374A
Authority
MX
Mexico
Prior art keywords
risperidone formulations
formulations
aqueous
aqueous risperidone
risperidone
Prior art date
Application number
MX9700374A
Other languages
English (en)
Inventor
Marc Karel Jozef Francois
Willy Maria Albert Carlo Dries
Original Assignee
Janssen Pharmeceutica N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26955530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9700374(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmeceutica N V filed Critical Janssen Pharmeceutica N V
Publication of MX9700374A publication Critical patent/MX9700374A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion trata de soluciones acuosas físico-químicamente estables de risperidona para su administracion oral y parenteral; procedimientos para preparar tales formulaciones.
MX9700374A 1994-07-11 1995-07-04 Formulaciones acuosas de risperidona. MX9700374A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/272,462 US5453425A (en) 1994-07-11 1994-07-11 Risperidone oral formulation
US08/429,435 US5616587A (en) 1994-07-11 1995-04-26 Aqueous risperidone formulations
PCT/EP1995/002615 WO1996001652A1 (en) 1994-07-11 1995-07-04 Aqueous risperidone formulations

Publications (1)

Publication Number Publication Date
MX9700374A true MX9700374A (es) 1997-04-30

Family

ID=26955530

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9700374A MX9700374A (es) 1994-07-11 1995-07-04 Formulaciones acuosas de risperidona.

Country Status (36)

Country Link
US (3) US5453425A (es)
EP (1) EP0769965B1 (es)
JP (1) JP2872412B2 (es)
KR (1) KR100212942B1 (es)
CN (1) CN1148226C (es)
AP (1) AP774A (es)
AT (1) ATE206931T1 (es)
AU (1) AU684193B2 (es)
BG (1) BG63070B1 (es)
BR (1) BR9508253A (es)
CA (1) CA2194564C (es)
CY (1) CY2268B1 (es)
CZ (1) CZ285204B6 (es)
DE (1) DE69523313T2 (es)
DK (1) DK0769965T3 (es)
EE (1) EE03426B1 (es)
ES (1) ES2165918T3 (es)
FI (1) FI116510B (es)
HR (1) HRP950397B1 (es)
HU (1) HU222352B1 (es)
IL (1) IL114525A (es)
MX (1) MX9700374A (es)
MY (1) MY114389A (es)
NO (1) NO320366B1 (es)
NZ (1) NZ289432A (es)
PH (1) PH31626A (es)
PL (1) PL179972B1 (es)
PT (1) PT769965E (es)
RO (1) RO116778B1 (es)
RU (1) RU2161965C2 (es)
SI (1) SI9500220B (es)
SK (1) SK282159B6 (es)
TR (1) TR199500778A1 (es)
TW (1) TW420615B (es)
WO (1) WO1996001652A1 (es)
ZA (1) ZA955720B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL314481A1 (en) 1993-11-19 1996-09-16 Janssen Pharmaceutica Nv Microencapsulated substituted 3-piperidinyl 1,2-benzoisoxazoles and 1,2-benzoisothiazoles
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
SE0103211D0 (sv) * 2001-09-27 2001-09-27 Pharmacia Ab New formulations and use thereof
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20060148826A1 (en) * 2002-08-23 2006-07-06 Ashish Gogia Stable aqueous solutions of risperidone and methods for their preparation
WO2004094415A1 (en) * 2003-04-22 2004-11-04 Synthon B.V. Risperidone monohydrochloride
PE20050285A1 (es) 2003-06-24 2005-06-09 Novartis Ag Composicion farmaceutica que comprende analogos ciclicos de somatostatina
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
ES2245252B1 (es) * 2004-06-15 2007-03-01 Farmalider, S.A. Solucion acuosa de risperidona para administracion oral.
ES2245891B1 (es) * 2004-07-09 2006-11-16 Clinmet S.L. "metodo para la obtencion de un excipiente universal para la administracion oral de principios activos farmaceuticos y composiciones de excipientes resultantes del metodo".
WO2006129160A2 (en) * 2005-06-01 2006-12-07 Aurobindo Pharma Limited Stable aqueous oral solution of risperidone
ES2323286T3 (es) * 2005-06-29 2009-07-10 Verisfield (Uk) Ltd. Composiciones farmaceuticas de risperidona en disolucion acuosa.
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
JP4922657B2 (ja) * 2006-05-09 2012-04-25 高田製薬株式会社 リスペリドン経口用液剤
WO2007138462A2 (en) * 2006-06-01 2007-12-06 Wockhardt Ltd Aqueous oral formulations of risperidone
JP2010531807A (ja) 2007-05-25 2010-09-30 トルマー セラピューティクス， インコーポレイテッド リスペリドン化合物の徐放送達製剤
US7776866B2 (en) * 2007-09-15 2010-08-17 Protia, Llc Deuterium-enriched risperidone
DK2234617T4 (da) * 2007-12-19 2024-12-16 Janssen Pharmaceutica Nv Doseringsskema forbundet med langtidsvirkende injicerbare paliperidonestere
CA3037010A1 (en) * 2009-01-20 2010-07-29 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Cente Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
EP2763676B1 (en) * 2011-10-03 2019-12-25 The University of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
SG11201703632WA (en) 2014-11-07 2017-06-29 Indivior Uk Ltd Buprenorphine dosing regimens
RU2765625C2 (ru) 2016-06-13 2022-02-01 Сайньюрекс Интернэшнл (Тайвань) Корп. Сокристаллы бензоата лития и их применения
DK3468944T3 (da) 2016-06-13 2023-02-06 Syneurx Int Taiwan Corp Co-krystaller af natriumbenzoat og anvendelser deraf
BR112019005542A2 (pt) * 2016-09-23 2019-06-18 Delpor Inc composições para compostos de agente terapêutico de pequenas moléculas
US10336679B2 (en) 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
RU2646812C1 (ru) * 2016-10-24 2018-03-07 Общество с ограниченной ответственностью "Трейдсервис" Жидкая лекарственная форма рисперидона и способ ее получения
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CN107260662A (zh) * 2017-06-21 2017-10-20 南京正科医药股份有限公司 一种利培酮口服溶液及其制备方法
CN107441037A (zh) * 2017-08-16 2017-12-08 南京正科医药股份有限公司 一种利培酮口服溶液
CN109589304A (zh) * 2017-10-01 2019-04-09 万特制药(海南)有限公司 利培酮口服溶液及其制备方法
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
CN112004538A (zh) * 2018-02-27 2020-11-27 德尔宝股份有限公司 小分子治疗剂化合物的组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337261A (en) * 1980-07-28 1982-06-29 Hoechst-Roussel Pharmaceuticals Inc. (1,2-Benzisoxazol)phenoxyacetic acids as diuretics
US4793992A (en) * 1987-03-25 1988-12-27 Redken Laboratories, Inc. Hair treatment composition
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
FR2641278B1 (fr) * 1989-01-05 1991-03-22 Lipha Piperidines, procedes de preparation et medicaments les contenant
DK203990D0 (da) * 1990-08-24 1990-08-24 Novo Nordisk As Piperazinylderivater
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
FR2796273B1 (fr) * 1999-07-15 2003-09-12 Oreal Composition a phase grasse liquide gelifiee par un polyamide a groupements ester terminaux

Also Published As

Publication number Publication date
WO1996001652A1 (en) 1996-01-25
PL179972B1 (pl) 2000-11-30
NO970051D0 (no) 1997-01-07
FI116510B (fi) 2005-12-15
IL114525A0 (en) 1995-11-27
IL114525A (en) 1999-06-20
JPH09511751A (ja) 1997-11-25
US5616587A (en) 1997-04-01
BG101106A (en) 1997-08-29
HRP950397A2 (en) 1997-10-31
HUT76826A (en) 1997-11-28
BR9508253A (pt) 1997-12-23
NO970051L (no) 1997-01-07
NZ289432A (en) 1998-05-27
ZA955720B (en) 1997-01-10
JP2872412B2 (ja) 1999-03-17
NO320366B1 (no) 2005-11-28
SI9500220A (en) 1996-02-29
PL318132A1 (en) 1997-05-12
BG63070B1 (bg) 2001-03-30
SI9500220B (sl) 2004-12-31
FI970109L (fi) 1997-01-10
TW420615B (en) 2001-02-01
AU684193B2 (en) 1997-12-04
CA2194564A1 (en) 1996-01-25
PT769965E (pt) 2002-04-29
KR970704472A (ko) 1997-09-06
FI970109A0 (fi) 1997-01-10
USRE39181E1 (en) 2006-07-11
ES2165918T3 (es) 2002-04-01
TR199500778A1 (tr) 1996-10-21
HU9700082D0 (en) 1997-02-28
HK1010691A1 (en) 1999-06-25
DE69523313T2 (de) 2002-06-27
MY114389A (en) 2002-10-31
ATE206931T1 (de) 2001-11-15
CZ285204B6 (cs) 1999-06-16
AU2927595A (en) 1996-02-09
DE69523313D1 (de) 2001-11-22
CN1155247A (zh) 1997-07-23
KR100212942B1 (ko) 1999-08-02
HU222352B1 (hu) 2003-06-28
EP0769965A1 (en) 1997-05-02
EP0769965B1 (en) 2001-10-17
AP774A (en) 1999-10-28
PH31626A (en) 1999-01-12
AP9700910A0 (en) 1997-01-31
RU2161965C2 (ru) 2001-01-20
CN1148226C (zh) 2004-05-05
SK2297A3 (en) 1997-09-10
DK0769965T3 (da) 2002-02-04
CY2268B1 (en) 2003-07-04
CZ2797A3 (en) 1997-07-16
RO116778B1 (ro) 2001-06-29
SK282159B6 (sk) 2001-11-06
EE9700009A (et) 1997-08-15
EE03426B1 (et) 2001-06-15
CA2194564C (en) 1997-12-16
HRP950397B1 (en) 2002-04-30
US5453425A (en) 1995-09-26

Similar Documents

Publication Publication Date Title
MY114389A (en) Aqueous risperidone formulations
AU7076887A (en) Nasal administration of drugs
CA2263561A1 (en) Thienopyrimidines
EP0326196A3 (en) Aqueous pharmaceutical preparation
IL112495A0 (en) Phenylacetic acid derivatives, their preparation and compositions containing them
PL325825A1 (en) Microemulsion for use as a carrier for administering active compounds
HUP9903174A2 (hu) Koenzim Q-10-et tartalmazó gyógyászati készítmény
CA2072573A1 (en) Treatment of human retroviral infections with 2',3'-dideoxyinosine
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
AU7294196A (en) Stable pharmaceutical forms of administration containing parathormone
FI95570C (fi) Menetelmä lääkinnällisesti vaikuttavien pyridatsinoni-3(2H)-onijohdannaisten valmistamiseksi
GR3006091T3 (es)
NZ336990A (en) Aqueous suspension for nasal administration comprising loteprednol and microcrystalline cellulose carmellose sodium
TW223061B (en) 9-(3-cyanophenyl)-3,4,6,7,9,10-hexahydro-1,8-(2h,5h)-acridinedione and pharmaceutical compositions containing same
AR242561A1 (es) Procedimiento para la preparacion de clorhidrato de s-(-)-1-propil-2',6'-pipecoloxilidida opticamente sustancialmente puro y procedimiento
BG102342A (en) Optical active derivative of phenylpyrimidine as an anlgesics
UA41880C2 (uk) Серотонінергічні похідні ерголіну і фармацевтична композиція
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
BG106534A (en) Oral solution containing galanthamine and a sweetening agent
AU580890B2 (en) P-acylaminobenzamides
AU4956193A (en) Stable, highly concentrated formulations of fluorescein derivatives
AU7935887A (en) Therapeutic agent for the treatment of peptic ulcer disease
NO971604L (no) Orale sabeluzolsuspensjoner
BG104452A (en) New derivatives of the methylenebisphosphonic acid
IL107242A0 (en) Derivatives of benzeneborinic acid, preparation thereof and use thereof as synthetic intermediates